14-Aug-2026
ACCESS Newswire (Tue, 4-Aug 8:46 AM ET)
ACCESS Newswire (Fri, 31-Jul 8:30 AM ET)
ACCESS Newswire (Wed, 15-Jul 8:30 AM ET)
ACCESS Newswire (Tue, 7-Jul 8:29 AM ET)
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
ACCESS Newswire (Mon, 22-Jun 9:00 AM ET)
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
ACCESS Newswire (Tue, 2-Jun 9:01 AM ET)
FDA Clears Path for enVVeno’s TAVVE Study, Targeting 3 Million Chronic Venous Insufficiency Patients
Market Chameleon (Wed, 29-Apr 4:48 AM ET)
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Envveno Medical trades on the NASDAQ stock market under the symbol NVNO.
As of August 14, 2026, NVNO stock price climbed to $10.99 with 1,437 million shares trading.
NVNO has a beta of 2.57, meaning it tends to be more sensitive to market movements. NVNO has a correlation of 0.03 to the broad based SPY ETF.
NVNO has a market cap of $7.34 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NVNO traded as high as $243.95 and as low as $8.67.
The top ETF exchange traded funds that NVNO belongs to (by Net Assets): VXF.
NVNO has underperformed the market in the last year with a price return of -93.0% while the SPY ETF gained +21.5%. However, in the short term, NVNO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.7% vs +4.0% return in SPY. But in the last 2 weeks, NVNO shares have been beat by the market, returning +3.7% compared to an SPY return of +3.9%.
NVNO support price is $10.15 and resistance is $11.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVNO shares will trade within this expected range on the day.
